



Press Release 9 September 2010

Medivir presenting at the National Swedish Hepatitis Meeting

~ Clinical update on TMC435 HCV-protease inhibitor ~

Medivir AB (OMX: MVIR), the biopharmaceutical company focused on infectious diseases caused by viruses, will today present a clinical update on its key drug, TMC435, a potential blockbuster therapy against Hepatitis C which is partnered with Tibotec, at the National Swedish Hepatitis Meeting.

Medivir's CSO, Prof Bertil Samuelsson, will give a presentation entitled 'Clinical update of TMC435 HCV-protease inhibitor' at 12:30 CEST on 9 September 2010 at the Nordic Sea Hotel in Stockholm. A copy of the presentation will be available on Medivir's website (www.medivir.se) after the meeting.

For more information, please contact:

Medivir

Rein Piir, CFO & VP Investor Relations

Office: +46 8 546 831 23

Mobile: +46 708 537 292

M:Communications

Mary-Jane Elliott / Emma Thompson

+44(0)20 7920 2345

Medivir@mcomgroup.com

About Medivir

Medivir is an established biopharmaceutical company focused on the development of high-value treatments mainly in infectious diseases. Medivir has world class expertise in polymerase and protease drug targets and drug development. Medivir has a strong R&D portfolio and has recently launched its first product, an innovative treatment for cold sores.

Xerese™/Xerclear™ is a treatment for cold sores, which has been approved in both the US and Europe. It is partnered with GSK to be sold OTC in Europe and Russia and by Meda in North America. Medivir have retained the Rx rights for Xerclear™ in Sweden and Finland.

Medivir's key pipeline asset, TMC435, a protease inhibitor, is in Phase IIb clinical development for Hepatitis C and is partnered with Tibotec.

For more information on Medivir, please see the company website: www.medivir.se